EMA Heeds Ombudsman’s Advice On Avoiding Perception Of Bias In Drug Evaluations
Changes Are In Response To An Inquiry By EU Ombudsman
Executive Summary
An inquiry by the EU Ombudsman has prompted the European Medicines Agency to introduce changes to ensure that its experts, who advise companies in the premarket phase, are not appointed to evaluate marketing applications for the same drugs.
You may also be interested in...
EMA In The Clear Over Transparency In COVID-19 Product Assessments
The European Ombudsman has closed an inquiry into the European Medicines Agency’s practices with regard to coronavirus vaccines and treatments.
EMA Gets Keys To New HQ And Restarts Some Stalled Activities
The European Medicines Agency has taken possession of its new HQ in Amsterdam and has hired 77 new staff members to make up for the severe staff losses it has witnessed on account of Brexit.
Major Inquiry Into EMA Pre-Submission Meetings And Bias Risk Concludes
The European Ombudsman has recommended how the European Medicines Agency can avoid even the perception that the decisions it takes on marketing authorization applications are influenced by the pre-submission interactions it has with drug developers.